Understanding the impact of HLA molecular mismatch in solid organ transplantation: Are we there yet?
Autor: | Annette M. Jackson, David F. Pinelli |
---|---|
Rok vydání: | 2020 |
Předmět: |
Human leukocyte antigen
Brief Communication Tacrolimus Cohort Studies immunosuppressant ‐ calcineurin inhibitor: tacrolimus immunosuppression / immune modulation clinical research / practice alloantibody Immunology and Allergy Medicine Humans Pharmacology (medical) kidney transplantation / nephrology monitoring: immune Transplantation business.industry autoimmunity Organ Transplantation United States Histocompatibility Immunology rejection business Solid organ transplantation Brief Communications |
Zdroj: | American Journal of Transplantation |
ISSN: | 1600-6143 |
Popis: | Clinicians have few tools to predict the risk of alloimmune injury that would guide immunosuppression management in renal transplant patients. We evaluated human leukocyte antigen (HLA)‐DR/DQ molecular mismatch to predict de novo donor‐specific antibodies (DSAs) during the first year of transplant and explored how differences in tacrolimus exposure may modulate this risk. HLA‐DR and ‐DQ eplet mismatches were determined between 444 donor‐recipient pairs in Denver, Colorado between 2007 and 2013. Previously defined mismatch thresholds stratified recipients into low‐ (N = 119), intermediate‐ (N = 153), and high‐ (N = 172) risk categories. The area under the curve for DSA at 1 year was 0.84 and 0.82 for HLA‐DR and HLA‐DQ eplet mismatches, respectively. Compared to low‐risk patients, there was a graded increase in risk of DR/DQ DSA in intermediate (HR 15.39, 95% CI 2.01‐118.09, p = .009) and high‐risk (HR 23.81, 95% CI 3.17‐178.66, p = 0.002) categories. Intermediate‐ and high‐risk patients with a mean tacrolimus 8 ng/ml had increased risk of DR/DQ DSA at 1 year (HR 2.34, 95% CI 1.05‐5.22, p = .04). HLA molecular mismatch represents a reproducible, objective, and clinically relevant tool to stratify patients by alloimmune risk and may help guide personalized immunosuppression management. DR/DQ molecular mismatch predicts the development of de novo donor‐specific antibodies after kidney transplantation, with a graded increase in risk for intermediate and high molecular mismatch patients that is modulated by differences in tacrolimus exposure. Jackson and Pinelli's editorial is on page 9. |
Databáze: | OpenAIRE |
Externí odkaz: |